PSMA Conjugate Synthesis for Targeted Prostate Cancer Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as hormonal therapy, radiation therapy, and chemotherapy, often have significant side effects and are not highly selective for prostate-specific membrane antigen (PSMA) expressing cells, leading to damage in non-target tissues like bones and liver.
Innovation Solution
Development of compounds capable of binding to PSMA with high affinity, allowing for targeted delivery of diagnostic, imaging, and therapeutic agents to PSMA expressing cells, using a process that includes resin-based reactions with various deprotecting agents and solvents to synthesize compounds like PSMA-617.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (hormonal therapy, radiation therapy, chemotherapy) are used for prostate cancer, then cancer treatment effectiveness is achieved, but significant side effects occur in non-target tissues such as bones and liver
Solution Approach 1:
The treatment approach segments the body into target (PSMA-expressing prostate cancer cells) and non-target tissues, delivering therapy selectively to the former while sparing the latter. The PSMA-targeted compounds act as carriers that segment the treatment effect, concentrating therapeutic action at the tumor site rather than systemically affecting all tissues.
Solution Approach 2:
PSMA serves as an intermediary biomarker on the cell surface that mediates between the therapeutic agent and the prostate cancer cell. The compounds bind to PSMA as an intermediary, which then facilitates internalization and delivers the therapeutic payload specifically to prostate cancer cells, avoiding direct damage to non-target tissues like bones and liver.
2Reliability
If PSMA-targeted compounds are developed for selective delivery, then treatment specificity to prostate cancer cells is improved, but the complexity of synthesis and purification processes increases
Solution Approach 1:
The synthesis process employs preliminary actions by using resin-based platforms to pre-attach and protect functional groups before final coupling. Protecting groups are installed in advance to prevent unwanted reactions during intermediate steps, and resin-based intermediates are prepared beforehand to streamline the overall synthesis pathway, reducing the complexity burden despite the multiple steps required for PSMA-targeted compound production.
3Manufacturing precision
If multiple synthesis steps with protecting groups are used to ensure compound purity, then manufacturing precision is improved, but production time and process complexity increase
Solution Approach 1:
The synthesis methodology utilizes parameter changes by switching between different reaction conditions (acidic, basic, neutral) and protecting group states to control reaction specificity. By changing the chemical environment parameters at each step, the process achieves high precision purity while managing time through efficient parameter transitions rather than prolonged single-step reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized compounds exhibit high affinity for PSMA and are efficacious in treating diseases caused by PSMA expressing cells, particularly prostate cancer, with the potential for reduced side effects and improved treatment specificity.
Implementation Method 1
contacting a resin-based compound of the formula A with a first deprotecting agent in a polar aprotic solvent to provide a resin-based compound of the formula A'
Implementation Method 2
the conjugates prepared by the processes described herein exhibit high affinity for PSMA
Data Source
AI summary
This disclosure relates to processes for preparing compounds that are useful in the treatment of disease, such as cancer, in mammals. In particular, the invention described herein pertains to processes for preparing compounds capable of targeting PSMA expressing cells and useful in the treatment of diseases caused by PSMA expressing cells, such as prostate cancer.